A complex interplay of drivers is at work in liver disease on the spectrum of NAFLD (non-alcoholic fatty liver... Read More
Taconic Awards Academic Grants to Advance Autoimmune, NASH, and Neuroscience Research As a company deeply committed to advancing human... Read More
Rare diseases affect roughly 30 million Americans, yet significant challenges remain in studying and curing these conditions. Since there... Read More
Genetically engineered animals are vital to drug discovery; yet, generating a relevant model involves key decision points. In this... Read More
Recent update to carcinogenicity study guidelines will transform how new drugs are evaluated, and selection of the Taconic Biosciences... Read More
Given the mounting evidence that the gut microbiome impacts disease development and progression, drug efficacy, and even the metabolism... Read More
Early life adversity can increase an individual's vulnerability to stress, which in turn increases their predisposition to psychiatric disorders.... Read More
Preclinical studies typically require a significant investment in genetically engineered models that are uniquely relevant to the study objective,... Read More
Avista to leverage industry expertise to support Taconic's growth in the large and expanding GEMs market NEW YORK —... Read More
FcResolv™ NOG Models Provide Greater Clarity and More Translatable Data Rensselaer, NY — October 24, 2022 - Taconic Biosciences,... Read More
During our Virtual NASH Symposium on August 25, Dr. Michele Vacca will present the keynote address on recapitulating translational... Read More
Despite having revolutionized cancer treatment, immunotherapy still demonstrates a wide range of efficacy across patients and tumor types. As... Read More
Welcome! Tell us a little about yourself